CellArk Bio Overview
- Year Founded
-
2024
- Status
-
Private
- Employees
-
49
- Latest Deal Type
-
Early Stage VC
- Investors
-
11
CellArk Bio General Information
Description
Developer of a cell regeneration technology designed to promote youth and beauty. The company's technology specializes in building a sustainable aesthetic market to improve the quality of human life through quality management and creates cosmetic medical devices and pharmaceuticals using tissue engineering technology, enabling youth to get safe, natural, and pain-free treatment.
Contact Information
Website
www.cellarkbio.comCorporate Office
- Room Number 1101, Building B, Songpa Terra Tower 2
- 201 Songpa-daero, Songpa-gu
- Seoul
- South Korea
Corporate Office
- Room Number 1101, Building B, Songpa Terra Tower 2
- 201 Songpa-daero, Songpa-gu
- Seoul
- South Korea
CellArk Bio Timeline
CellArk Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC | 24-Mar-2026 | Completed | Generating Revenue | |||
| 1. Early Stage VC (Series A) | 17-Mar-2025 | Completed | Generating Revenue |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
CellArk Bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
CellArk Bio Patents
CellArk Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026147196-A1 | Composition for improving solubility of thiazolidinedione-based compound, and use thereof | Pending | 31-Dec-2024 |
CellArk Bio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
CellArk Bio Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Bridge Alliance Partners | Venture Capital | Minority | ||
| Pathway Partners (Korea) | Venture Capital | Minority | ||
| The Founders | Corporation | Minority | ||
| Wonik Investment Partners | PE/Buyout | Minority | ||
| BNH Investment | Venture Capital | Minority |
CellArk Bio FAQs
-
When was CellArk Bio founded?
CellArk Bio was founded in 2024.
-
Where is CellArk Bio headquartered?
CellArk Bio is headquartered in Seoul, South Korea.
-
What is the size of CellArk Bio?
CellArk Bio has 49 total employees.
-
What industry is CellArk Bio in?
CellArk Bio’s primary industry is Other Devices and Supplies.
-
Is CellArk Bio a private or public company?
CellArk Bio is a Private company.
-
What is CellArk Bio’s current revenue?
The current revenue for CellArk Bio is .
-
How much funding has CellArk Bio raised over time?
CellArk Bio has raised $40.1M.
-
Who are CellArk Bio’s investors?
Bridge Alliance Partners, Pathway Partners (Korea), The Founders, Wonik Investment Partners, and BNH Investment are 5 of 11 investors who have invested in CellArk Bio.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
